HeartLab announces partnership with InVision Medical Technology

HeartLab announced a partnership with InVision Medical Technology focused on bringing its artificial intelligence (AI) algorithms to Australia and New Zealand, subject to regulatory approval.

What the partnership covers

InVision describes its AI tools as designed to support the interpretation of heart ultrasounds and the identification of disease that may otherwise go undiagnosed. The companies said the partnership would bring this technology to HeartLab customers in Australia and New Zealand for the first time.

The agreement covers AI-based detection of cardiac amyloidosis and assessment of heart function. Availability remains subject to regulatory approval in each market.

What the leaders said

HeartLab CEO Will Hewitt described the partnership as an opportunity to improve access to emerging medical technology in the region.

“Historically advanced new medical technologies have taken years to become available, particularly in places like New Zealand which are not major markets for medical device companies. It’s exciting to be able to bring this cutting edge technology to the hundreds of people that log into HeartLab each day.”

Will Hewitt, HeartLab CEO

“We are excited to partner with HeartLab’s innovative cardiology imaging platform to democratize access to next-generation artificial intelligence diagnostic testing. Echocardiography, as the most common form of cardiac imaging, is a vital opportunity for early disease detection. As a rare form of heart failure, cardiac amyloidosis is frequently missed in routine care, and AI can serve as a ‘safety-net’ for uncommon disease detection.”

Dr David Ouyang, InVision CEO

Availability

At the time of the announcement, the companies expected the technology to become available in Australia and New Zealand in the first half of 2026, pending regulatory approval. InVision Precision Cardiac Amyloid and Precision LVEF was already FDA cleared in the United States.

Contact HeartLab for current product and regulatory availability in your region.